Compare PTC & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTC | WST |
|---|---|---|
| Founded | 1985 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.2B | 18.5B |
| IPO Year | 1995 | 2004 |
| Metric | PTC | WST |
|---|---|---|
| Price | $146.37 | $321.11 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 7 |
| Target Price | $183.09 | ★ $325.86 |
| AVG Volume (30 Days) | ★ 1.2M | 850.2K |
| Earning Date | 05-06-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 0.30% |
| EPS Growth | ★ 94.87 | 1.49 |
| EPS | ★ 6.35 | 1.92 |
| Revenue | $2,739,226,000.00 | ★ $2,886,900,000.00 |
| Revenue This Year | $0.03 | $6.76 |
| Revenue Next Year | $6.20 | $6.22 |
| P/E Ratio | ★ $97.81 | $163.59 |
| Revenue Growth | ★ 19.18 | 1.95 |
| 52 Week Low | $130.89 | $203.74 |
| 52 Week High | $219.69 | $322.34 |
| Indicator | PTC | WST |
|---|---|---|
| Relative Strength Index (RSI) | 62.79 | 76.38 |
| Support Level | $147.43 | $234.43 |
| Resistance Level | $180.37 | $321.34 |
| Average True Range (ATR) | 4.07 | 8.84 |
| MACD | 1.18 | 1.96 |
| Stochastic Oscillator | 69.34 | 97.45 |
PTC is a US-based global company that offers high-end computer-assisted design, product lifecycle management, and augmented reality solutions that industrial manufacturers commonly use on factory floors. Founded in 1985, PTC is a major player in parametric design and serves some of the world's most well-known equipment manufacturers, such as Caterpillar, Garmin, and Thermo Fisher.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.